<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1166" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1166/" /><meta name="ncbi_pagename" content="Oculocutaneous Albinism Type 1 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Oculocutaneous Albinism Type 1 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Oculocutaneous Albinism Type 1" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/05/16" /><meta name="citation_author" content="Richard Alan Lewis" /><meta name="citation_pmid" content="20301345" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1166/" /><meta name="citation_keywords" content="OCA1" /><meta name="citation_keywords" content="OCA1" /><meta name="citation_keywords" content="Oculocutaneous Albinism Type 1A (OCA1A)" /><meta name="citation_keywords" content="Oculocutaneous Albinism Type 1B (OCA1B)" /><meta name="citation_keywords" content="Tyrosinase" /><meta name="citation_keywords" content="TYR" /><meta name="citation_keywords" content="Oculocutaneous Albinism Type 1" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Oculocutaneous Albinism Type 1" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Richard Alan Lewis" /><meta name="DC.Date" content="2013/05/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1166/" /><meta name="description" content="Oculocutaneous albinism type 1 (OCA1) is characterized by hypopigmentation of the skin and hair and the distinctive ocular changes found in all types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia with substantial reduction in visual acuity, usually in the range of 20/100 to 20/400; and misrouting of the optic nerve fiber radiations at the chiasm, resulting in strabismus, reduced stereoscopic vision, and altered visually evoked potentials (VEP). Individuals with OCA1A have white hair, white skin that does not tan, and fully translucent irides, none of which darken with age. At birth, individuals with OCA1B have white or very light yellow hair that darkens minimally with age, white skin that over time develops some minimal generalized pigment and may tan slightly with judicious sun exposure, and blue irides that darken to green/hazel or light brown/tan with age, although transillumination defects persist. Visual acuity may be 20/60 or better in some eyes." /><meta name="og:title" content="Oculocutaneous Albinism Type 1" /><meta name="og:type" content="book" /><meta name="og:description" content="Oculocutaneous albinism type 1 (OCA1) is characterized by hypopigmentation of the skin and hair and the distinctive ocular changes found in all types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia with substantial reduction in visual acuity, usually in the range of 20/100 to 20/400; and misrouting of the optic nerve fiber radiations at the chiasm, resulting in strabismus, reduced stereoscopic vision, and altered visually evoked potentials (VEP). Individuals with OCA1A have white hair, white skin that does not tan, and fully translucent irides, none of which darken with age. At birth, individuals with OCA1B have white or very light yellow hair that darkens minimally with age, white skin that over time develops some minimal generalized pigment and may tan slightly with judicious sun exposure, and blue irides that darken to green/hazel or light brown/tan with age, although transillumination defects persist. Visual acuity may be 20/60 or better in some eyes." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1166/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/oca1/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1166/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D661DE0403F8100000000095B034C.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1166_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1166_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-oa/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/oca2/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1166_"><span class="title" itemprop="name">Oculocutaneous Albinism Type 1</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: OCA1</div><p class="contrib-group"><span itemprop="author">Richard Alan Lewis</span>, MD, MS.</p><a data-jig="ncbitoggler" href="#__NBK1166_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1166_ai__"><div class="contrib half_rhythm"><span itemprop="author">Richard Alan Lewis</span>, MD, MS<div class="affiliation small">Cullen Eye Institute<br />Baylor College of Medicine<br />Houston, Texas<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.mcb@siwelr" class="oemail">ude.mcb@siwelr</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">January 19, 2000</span>; Last Update: <span itemprop="dateModified">May 16, 2013</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="oca1.Summary" itemprop="description"><h2 id="_oca1_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Oculocutaneous albinism type 1 (OCA1) is characterized by hypopigmentation of the skin and hair and the distinctive ocular changes found in all types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia with substantial reduction in visual acuity, usually in the range of 20/100 to 20/400; and misrouting of the optic nerve fiber radiations at the chiasm, resulting in strabismus, reduced stereoscopic vision, and altered visually evoked potentials (VEP). Individuals with OCA1A have white hair, white skin that does not tan, and fully translucent irides, none of which darken with age. At birth, individuals with OCA1B have white or very light yellow hair that darkens minimally with age, white skin that over time develops some minimal generalized pigment and may tan slightly with judicious sun exposure, and blue irides that darken to green/hazel or light brown/tan with age, although transillumination defects persist. Visual acuity may be 20/60 or better in some eyes.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of OCA1 is established by clinical findings of profound hypopigmentation of the skin and hair and characteristic ocular findings. Molecular genetic testing of <i>TYR</i> (encoding tyrosinase) is used infrequently in diagnosis, except to distinguish between types 1A and 1B, as the phenotypes may be nearly identical in the first year of life.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Correction of refractive errors with spectacles or (when age-appropriate) contact lenses may improve visual acuity; strabismus surgery can be considered for either functional (improved peripheral fusion) or cosmetic reasons. Hats with brims and dark glasses or transition lenses often reduce discomfort in bright light (photodysphoria).</p><p>Protection from sun exposure with appropriate skin-covering clothing and sunscreens prevents burning, consequent skin damage, and the enhanced risk of skin cancer. Skin cancer, including a slightly enhanced risk for cutaneous melanoma, is treated as for the general population.</p><p><i>Surveillance:</i> Annual ophthalmologic examination to reassess refractive errors and strabismus; routine skin examination of adults for evidence of sun-related skin damage and/or pre-cancerous or cancerous lesions.</p><p><i>Agents/circumstances to avoid:</i> Prolonged sun exposure.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>OCA1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. In most situations, the parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes, and therefore each carries one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>. Heterozygotes (carriers) are asymptomatic. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing of pregnancies at increased risk are possible when both pathogenic variants in an affected family member are known.</p></div></div><div id="oca1.GeneReview_Scope"><h2 id="_oca1_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="oca1.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1166/table/oca1.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca1.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oca1.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oculocutaneous Albinism Type 1: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_oca1.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Oculocutaneous albinism type 1A (OCA1A)</div></li><li class="half_rhythm"><div>Oculocutaneous albinism type 1B (OCA1B)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#oca1.Nomenclature">Nomenclature</a>.</p></div></dd></dl></div></div></div></div><div id="oca1.Diagnosis"><h2 id="_oca1_Diagnosis_">Diagnosis</h2><div id="oca1.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>The diagnosis of oculocutaneous albinism type 1 (OCA1) [<a class="bk_pop" href="#oca1.REF.creel.1990.193">Creel et al 1990</a>] is established by the presence of the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Hypopigmentation of the skin and hair (including brows and lashes) on physical examination</div></li><li class="half_rhythm"><div class="half_rhythm">Infantile nystagmus (usually noticed between ages 3 and 12 weeks)</div></li><li class="half_rhythm"><div class="half_rhythm">Markedly reduced iris pigment with iris transillumination</div></li><li class="half_rhythm"><div class="half_rhythm">Reduced retinal (pigment epithelial) pigmentation with visualization of the choroidal blood vessels on ophthalmoscopic examination</div></li><li class="half_rhythm"><div class="half_rhythm">Foveal hypoplasia associated with substantial reduction in visual acuity</div></li><li class="half_rhythm"><div class="half_rhythm">Misrouting of the optic nerve fiber projections at the optic chiasm frequently associated with strabismus (that may not develop until later in infancy), reduced stereoscopic vision, and altered visually evoked potentials (VEP)</div><div class="half_rhythm">Note: The VEP is performed with a technique specifically designed to demonstrate selective misrouting; thus, a conventional simultaneous binocular VEP will not demonstrate this anomaly. Normal routing of the optic nerves, demonstrated with a selective VEP, excludes the diagnosis of albinism/OCA. The VEP is not necessary for the diagnosis of albinism because misrouting is implied by the observation of strabismus and reduced stereoscopic vision. In some persons with mild hypopigmentation (a few with OCA1B) and foveal hypoplasia and no obvious nystagmus, a VEP may be a useful adjunct to demonstrate misrouting of the retinal to occipital projections [<a class="bk_pop" href="#oca1.REF.creel.1990.193">Creel et al 1990</a>, <a class="bk_pop" href="#oca1.REF.pott.2003.137">Pott et al 2003</a>]. MRI studies may demonstrate misrouting but this approach is not validated sufficiently to replace VEP [<a class="bk_pop" href="#oca1.REF.schmitz.2003.16">Schmitz et al 2003</a>].</div></li></ul></div><div id="oca1.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p><b>Gene.</b>
<i>TYR</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause oculocutaneous albinism type 1 [<a class="bk_pop" href="#oca1.REF.jeffery.1997.95">Jeffery et al 1997</a>, <a class="bk_pop" href="#oca1.REF.simeonov.2013.827">Simeonov et al 2013</a>].</p><p>Most individuals with OCA1 are compound heterozygotes with different paternal and maternal <i>TYR</i> pathogenic variants. No pathogenic variants in the proximal promoter of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been identified.</p><p>Evidence that additional undetected pathogenic variants are responsible for OCA1 comes from individuals with the OCA1A <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with only a single identifiable <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, but who are likely to be compound heterozygotes with a second, as-yet unidentified, pathogenic variant.</p><div id="oca1.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in OCA1</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1166/table/oca1.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca1.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_3" style="text-align:left;vertical-align:middle;">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="2" scope="col" colspan="1" headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_4" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5" id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">2 pathogenic variants</th><th headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5" id="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></th></tr></thead><tbody><tr><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TYR</i></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4</sup></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Sequence variants&#x000a0;<sup>5</sup></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OCA1A</td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5 hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%-90%&#x000a0;<sup>6</sup></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5 hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%-20%</td></tr><tr><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_4" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">OCA1B</td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5 hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">37%</td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5 hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">63%&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>8</sup></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exon or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions&#x000a0;<sup>9</sup></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Both forms</td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5 hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%&#x000a0;<sup>9</sup></td><td headers="hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_1_5 hd_h_oca1.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="oca1.TF.1.1"><p class="no_margin">See <a href="/books/NBK1166/#oca1.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="oca1.TF.1.2"><p class="no_margin">See <a href="#oca1.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="oca1.TF.1.3"><p class="no_margin">Data are only estimates only, based on clinical, assumed diagnoses. In early life, often before age one year, it is difficult to distinguish OCA1A from OCA1B. Other forms of OCA2-4 may result in light pigmentation that may be difficult to distinguish from OCA1, especially OCA1B. Mild forms of albinism are underdiagnosed and confused with other forms of early-onset, infantile nystagmus.</p></div></dd><dt>4. </dt><dd><div id="oca1.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, partial-, whole-, or multigene deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="oca1.TF.1.5"><p class="no_margin">In some populations, laboratories may only sequence select exons or specific targeted variants</p></div></dd><dt>6. </dt><dd><div id="oca1.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#oca1.REF.hutton.2008.2442">Hutton &#x00026; Spritz [2008]</a>, <a class="bk_pop" href="#oca1.REF.rooryck.2008.583">Rooryck et al [2008]</a>, <a class="bk_pop" href="#oca1.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov et al [2009]</a>, <a class="bk_pop" href="#oca1.REF.wei.2010.716">Wei et al [2010]</a></p></div></dd><dt>7. </dt><dd><div id="oca1.TF.1.7"><p class="no_margin">This estimate includes individuals who may have milder forms of oculocutaneous albinism (caused by pathogenic variants in genes other than <i>TYR</i>) and who, incidentally, also carry one <i>TYR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div></dd><dt>8. </dt><dd><div id="oca1.TF.1.8"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not readily detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA; included in the variety of methods that may be used are: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>9. </dt><dd><div id="oca1.TF.1.9"><p class="no_margin">Large deletions are quite rare (<a href="http://www.ifpcs.org/albinism/oca1mut.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Albinism Database</a>).</p></div></dd></dl></div></div></div></div><div id="oca1.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of OCA1 is usually based on clinical findings, especially for OCA1A. Molecular genetic testing is rarely necessary for diagnosis except in those individuals who develop some cutaneous, hair, and ocular pigment after the first year of life, particularly if the light pigmentation is confused with the clinical appearance of infants and children with OCA2.</p></div></div><div id="oca1.Clinical_Characteristics"><h2 id="_oca1_Clinical_Characteristics_">Clinical Characteristics</h2><div id="oca1.Clinical_Description"><h3>Clinical Description</h3><p>Individuals with all variations of OCA1 have white or nearly white scalp hair, brows, and lashes; white skin; and blue irides with extensive transillumination at birth. The presence of white scalp hair at birth should not be the exclusive clinical criterion for OCA1 because some persons with OCA2 may seem exceedingly fair in the first six to twelve months of life as well.</p><p>The claim of "white" scalp hair is not universally understood in some infants because of sparse, short hair, and because of the discoloration that occurs with some yellow-tinted shampoos. Parents may describe hair that is light yellow/blond as "white." In families with darker constitutional pigmentation, the white hair and skin are an immediate indication of hypopigmentation, and the diagnosis of OCA1 may be suspected at birth. In families with lighter constitutional pigmentation, the presence of a "towheaded" child may not seem unusual and the diagnosis of oculocutaneous albinism may be suspected only after the ocular findings of nystagmus, photodysphoria, and reduced visual function are noted. Indeed, the initial diagnosis of oculocutaneous albinism may be delayed into adolescence until confirmed by an ophthalmologist aware of the spectrum of its clinical features.</p><p>Rarely, children with albinism have been reported to have nystagmus at birth; however, most children with albinism develop nystagmus between ages three weeks and three months. The nystagmus can be very rapid in early life but its speed and amplitude generally slow with time; however, nearly all individuals with albinism have nystagmus throughout their lives. Nystagmus is more noticeable when an individual is tired, ill, or anxious, and less marked when s/he is well rested.</p><p>Many years of unprotected exposure to solar radiation of lightly pigmented skin may result in coarse, rough, thickened skin (pachydermia), solar keratoses (premalignant lesions), and skin cancer, both basal cell carcinoma and squamous cell carcinoma. Melanoma is rare in individuals with OCA, but may occur because dermal melanocytes are present. Skin cancer is unusual in individuals with OCA1 in the US because of the availability of sunscreens, the social acceptability of wearing clothes that cover most of the exposed skin, and the reality that individuals with albinism can be educated to minimize unprotected solar exposure. In regions of the planet where solar exposure is extensive and sunscreen difficult to obtain, the malignant cutaneous manifestations of oculocutaneous albinism are life-shortening.</p><p>OCA1 is divided into two categories: OCA1A, associated with no melanin synthesis in any tissue, and OCA1B, associated with minimal amounts of melanin synthesis in the hair, skin, and eyes. The ocular features of OCA1A and OCA1B are identical except for the amount of iris pigment.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>OCA1A.</b> Affected individuals have white hair, brows, and lashes, and white skin at birth. The skin stays white throughout life in all ethnic groups and invariably burns but does not tan. Skin lesions such as nevi are pink and unpigmented. The irides are blue and fully translucent at birth and remain so throughout life. Nystagmus continues and the retinal pigment epithelium does not develop melanin pigment. Best correctable visual acuity ranges between 20/100 and 20/400, unless strabismic amblyopia adds to the deficit.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>OCA1B.</b> Affected individuals typically have white or very light off-white (minimally yellow) hair at birth and develop observable light yellow hair color by age one to three years. The development of pigment in scalp hair is progressive and hair color usually goes through the stages of light yellow to light blond to golden blond to dark blond to light brown, but may stop at any color. The color of eyebrow hair is similar to that of the scalp hair, but the eyelash hair often turns mildly darker than the scalp hair.</div><div class="half_rhythm">The skin color remains white and burns in prolonged solar exposure but may develop some generalized tan. Lightly pigmented nevi and freckles appear with time.</div><div class="half_rhythm">Iris color may remain blue or change slowly in adolescence to a green/hazel or light tan color. Fine granular pigment may develop in the retina. The evolution of pigment in the iris and/or retina does not affect the nystagmus, which persists throughout life but does tend to dampen in speed and amplitude with age. Best corrected visual acuity is usually between 20/100 and 20/200, and tends to improve slowly until the late teens.</div></li></ul><p>Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals report modest improvements in visual acuity over time; however, part of the response may be improved understanding of the ophthalmic acuity tests with maturation of the child. No longitudinal data have been published to firmly assess the frequency or extent of visual "improvement" over time. It is critically important that all parents of affected children realize that, although visually impaired, children with albinism never lose the visual acuity that they achieve, unless an intervening event such as amblyopia occurs.</p></div><div id="oca1.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>OCA1A</b> is caused by <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants in <i>TYR</i> that produce a completely inactive or an incomplete tyrosinase enzyme polypeptide [<a class="bk_pop" href="#oca1.REF.gr_nskov.2007.43">Gr&#x000f8;nskov et al 2007</a>, <a class="bk_pop" href="#oca1.REF.simeonov.2013.827">Simeonov et al 2013</a>]. The total lack of tyrosinase enzyme function blocks the first step of the melanin biosynthetic pathway and, thus, no melanin forms in any melanocyte.</p><p><b>OCA1B</b> is caused by pathogenic variants in <i>TYR</i> that produce a partially active or <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> tyrosinase enzyme [<a class="bk_pop" href="#oca1.REF.gr_nskov.2007.43">Gr&#x000f8;nskov et al 2007</a>, <a class="bk_pop" href="#oca1.REF.simeonov.2013.827">Simeonov et al 2013</a>]. Affected individuals may be <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a single hypomorphic variant, <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for two different hypomorphic variants, or compound heterozygous for a hypomorphic and a <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> or <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variant.</p></div><div id="oca1.Nomenclature"><h3>Nomenclature</h3><p>OCA1A is the classic "tyrosinase-negative" OCA <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, but the term "tyrosinase-negative OCA" should no longer be used.</p><p>In the past, numerous clinical descriptions have attempted to quantitate the amount of pigment in persons with OCA, such as minimal pigment OCA, platinum OCA, temperature-sensitive OCA, and yellow OCA. Still, no universal nomenclature has been established for the various levels of pigmentation resulting from combinations of <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> alleles and, indeed, the overlap of clinical phenotypes with variants of OCA2.</p></div><div id="oca1.Prevalence"><h3>Prevalence</h3><p>OCA1 is estimated to occur at a frequency of approximately 1/40,000 in most populations throughout the world. Most individuals with OCA1 identified to date are those with OCA1A who are diagnosed by the obvious <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. The frequency of OCA1B is unknown.</p><p>The calculated <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency for OCA1 is approximately 1/100 in most populations.</p></div></div><div id="oca1.Genetically_Related_Disorders"><h2 id="_oca1_Genetically_Related_Disorders_">Genetically Related Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>TYR</i>.</p></div><div id="oca1.Differential_Diagnosis"><h2 id="_oca1_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Albinism.</b> The <i>ocular</i> features of all types of oculocutaneous albinism (OCA) and <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> ocular albinism are similar, and the terms "OCA" and "albinism" can be used interchangeably for these ocular manifestations.</p><p>Biallelic <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants of <i>TYR</i> are the only known cause of oculocutaneous albinism with white hair, white skin, and "blue" eyes (OCA1A). As noted in <a href="#oca1.Clinical_Characteristics">Clinical Characteristics</a>, the identification of white hair may be difficult because of the sparsity of scalp hair, brows, and lashes in a young child and the different perceptions by family members to describe what qualifies as "white" hair.</p><p>The differential diagnosis for individuals with albinism who have pigment in the skin and hair (OCA1B) includes <a href="/books/n/gene/oca2/">OCA2</a>, OCA3, <a href="/books/n/gene/oca4/">OCA4</a>, <a href="/books/n/gene/hps/">Hermansky-Pudlak syndromes</a> 1-7, and <a href="/books/n/gene/x-oa/">X-linked (Nettleship-Falls) ocular albinism</a> (OA1). Previous studies suggested the existence of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> ocular albinism, presenting with reportedly normal skin and hair pigment in males and females in a sibship; however, this interpretation seems to have been incorrect, and individuals with this apparent <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are now recognized to be part of the spectrum of OCA1B and OCA2. Recently another form of oculocutaneous albinism has been associated with pathogenic variants in <i>C10orf11</i>, a melanocyte-differentiation <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#oca1.REF.gr_nskov.2013.415">Gr&#x000f8;nskov et al 2013</a>], and others remain to be discovered.</p><p><a href="/books/n/gene/oca2/"><b>Oculocutaneous albinism type 2</b></a>
<b>(OCA2)</b> is characterized by hypopigmentation of the skin and hair and the characteristic ocular changes found in all types of albinism, including nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with strabismus, reduced stereoscopic vision, and altered visual evoked potentials (VEP). Vision is stable to slowly improving after early childhood until mid- to late teens, and no major change or loss of established visual acuity occurs related to the albinism. The amount of cutaneous pigmentation in OCA2 ranges from minimal to near-normal.</p><p>Newborns with OCA2 almost always have lightly pigmented hair, brows, and lashes, with color ranging from light yellow to blond to brown. Hair color may darken with age but does not vary substantially from adolescence to adulthood. Brown OCA, initially identified in Africans and African Americans with light brown hair and skin, is part of the spectrum of OCA2. The diagnosis of OCA2 is based on clinical findings. OCA2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. <i>OCA2</i> (previously called <i>P</i>) is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants are known to cause OCA2.</p><p><b>OCA3</b> is caused by pathogenic variants in <i>TYRP1</i>, encoding tyrosinase-related protein 1, which stabilizes <i>TYR</i> in large molecular complexes and without which <i>TYR</i> is degraded rapidly [<a class="bk_pop" href="#oca1.REF.kobayashi.2007.4261">Kobayashi &#x00026; Hearing 2007</a>]. Since the <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a> is necessary to synthesize the black/brown eumelanin but not the reddish pheomelanin, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> for OCA3 is a milder OCA in which <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals accumulate reddish pigment in their hair and skin, particularly noticeable in families of African ancestry. OCA3 is also inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/oca4/"><b>Oculocutaneous albinism type 4</b></a>
<b>(OCA4)</b> is characterized by hypopigmentation of the skin and hair plus the ocular characteristics of all other types of albinism. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near-normal. Newborns with OCA4 usually have some pigment in their hair, the color ranging from silvery white to light yellow. Hair color may darken with time but does not vary significantly from childhood to adulthood. This form of albinism is rarer than OCA2, except in the Japanese population.</p><p><i>SLC45A2</i> (previously called <i>MATP</i> and <i>AIM1</i>) is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is known to cause OCA4. <i>SLC45A2</i> encodes membrane-associated transporter protein, the human ortholog to the mouse gene <i>Underwhite</i> [<a class="bk_pop" href="#oca1.REF.newton.2001.981">Newton et al 2001</a>]. OCA4 was identified initially in one male of Turkish origin. Studies now suggest that this is the second most common type of OCA in Japanese individuals [<a class="bk_pop" href="#oca1.REF.inagaki.2004.466">Inagaki et al 2004</a>]. Because OCA2 and OCA4 are phenotypically similar, it is not possible to diagnose OCA4 accurately only on clinical findings. OCA4 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/hps/"><b>Hermansky-Pudlak syndromes</b></a>
<b>(HPS)</b> are nine multisystem disorders characterized by oculocutaneous albinism, a bleeding diathesis resulting from a platelet storage pool deficiency, and, in some cases, pulmonary fibrosis or granulomatous colitis evolving with age. The albinism is characterized by: hypopigmentation of the skin and hair; and ocular findings of reduced iris pigment with iris transillumination, reduced retinal pigment, foveal hypoplasia with significant reduction in visual acuity (usually in the range of 20/50 to 20/400), nystagmus, and increased crossing of the optic nerve fibers. Hair color ranges from white to brown; skin color ranges from white to olive and is usually a shade lighter than that of other family members. The bleeding diathesis can result in easy bruising, frequent epistaxis, gingival bleeding, postpartum hemorrhage, colonic bleeding, and prolonged bleeding with menses or after tooth extraction, circumcision, and other surgeries. Pulmonary fibrosis, a restrictive lung disease, typically causes symptoms in the early thirties and progresses to death within a decade. Granulomatous colitis is severe in about 15% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>The diagnosis of HPS is established by clinical findings of hypopigmentation of the skin and hair, characteristic eye findings, and demonstration of absent dense bodies on whole mount electron microscopy of platelets. Biallelic pathogenic variants in <i>HPS1</i>, <i>AP3B1</i>, <i>HPS3</i>, <i>HPS4</i>, <i>HPS5</i>, <i>HPS6</i>, <i>DTNBP1</i>, <i>BLOC1S3</i>, or <i>BLOC1S6</i> are known to be associated with HPS. HPS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><a href="/books/n/gene/x-oa/"><b>X-linked ocular albinism</b></a>
<b>(OA1)</b> is a disorder of melanosome biogenesis leading to minor skin manifestations and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> and persistent visual impairment in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males. OA1 is characterized by infantile nystagmus, reduced visual acuity, hypopigmentation of the iris pigment epithelium and the ocular fundus, and foveal hypoplasia in affected males. Significant refractive errors, reduced or absent binocular functions, photoaversion, and strabismus are common. OA1 is a non-progressive disorder and the visual acuity remains stable throughout life, often slowly improving into the mid-teens. A diagnosis of ocular albinism (OA) is probable in the presence of infantile nystagmus, iris translucency, substantial hypopigmentation of the ocular fundus periphery in males with mildly hypopigmented skin (most notably when compared to unaffected sibs), foveal hypoplasia, reduced visual acuity, and aberrant optic pathway projection as demonstrated by crossed asymmetry of the cortical responses on visual evoked potential testing (VEP).</p><p>OA1 is caused by pathogenic variants in <i>GPR143</i> (formerly <i>OA1</i>). <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> inheritance is documented by either a family history consistent with X-linked inheritance or the presence of typical <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> signs (irregular retinal pigmentation and partial iris transillumination) in an <a class="def" href="/books/n/gene/glossary/def-item/obligate-carrier/">obligate carrier</a> female.</p><p><a href="/books/n/gene/chediak-higashi/"><b>Chediak-Higashi syndrome</b></a>
<b>(CHS)</b> is characterized by partial oculocutaneous albinism (OCA), immunodeficiency, and a mild bleeding tendency. Approximately 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop an accelerated phase, a lymphoproliferative infiltration of the bone marrow and reticuloendothelial system. Adolescents and adults with atypical CHS and children with classic CHS who have successfully undergone allogenic hematopoietic stem cell transplantation (HSCT) develop neurologic findings during early adulthood.</p><p>Ophthalmologic findings, history of recurrent or severe infections, and abnormal platelet aggregation studies should prompt evaluation for CHS. Diagnosis is based on identification of abnormal WBC granules on blood smear. Biallelic <i>LYST</i> pathogenic variants are causative. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><b>Congenital motor nystagmus.</b> Congenital motor nystagmus is a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that presents as infantile nystagmus associated with reduced visual acuity. Some individuals with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> motor nystagmus have been reported to have retinal hypopigmentation and foveal abnormalities; however, the studies were done before the molecular analysis of the different types of OCA was available, implying that the populations may have included individuals with OCA who were diagnosed incorrectly with infantile nystagmus. The visually evoked potential (VEP) analysis to evaluate misrouting of the nerve fibers from the optic nerves is normal in congenital motor nystagmus. A single <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (<i>FRMD7</i>) for congenital infantile nystagmus has been reported.</p><p><a href="/books/n/gene/xl-nystag/"><b><i>FRMD7</i>-related infantile nystagmus</b></a>
<b>(FIN)</b> is an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder characterized by either the onset of horizontal, conjugate, gaze-dependent nystagmus in the first six months of life or periodic alternating nystagmus (with cyclical changes of nystagmus direction) of infantile onset. Binocular vision and color vision are normal and visual acuity is typically better than 6/12. An abnormal head posture is seen in approximately 15% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. The eyes are structurally normal and electrophysiologic studies, such as visual evoked potential (VEP) and electroretinogram (ERG), are normal. Affected females report slightly better visual acuity than affected males; however, no differences between males and females in the amplitude, frequency, and waveform of nystagmus are observed. The diagnosis is based on clinical findings and the presence of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>FRMD7</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in males and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>FRMD7</i> pathogenic variant in females.</p><p><b>Other considerations.</b> Additional confusion may occur among infants with blue cone monochromacy (males, <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>) or rod monochromacy (both genders, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>) in which nystagmus begins early in life, the foveas are underdeveloped, and myopia is common, leading to an exaggerated impression of underpigmented retinas. The severe loss of color perception clinically and the electroretinographic responses of abnormal cone and rod signals should separate these two entities from the albinisms. Hypopigmentation of hair, skin, and fundus and iris transillumination are not features.</p><p>Many other ocular disorders present with infantile nystagmus; that differential diagnosis is beyond the scope of this review.</p><p>See <a href="http://www.omim.org/phenotypicSeries/PS203100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Oculocutaneous Albinism: OMIM Phenotypic Series</a>, a table of similar phenotypes that are genetically diverse.</p></div><div id="oca1.Management"><h2 id="_oca1_Management_">Management</h2><div id="oca1.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed oculocutaneous albinism type 1 (OCA1), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Complete ophthalmologic evaluation, including assessment for the presence of nystagmus, ocular alignment and strabismus, iris pigmentation and transillumination, dilated retinal examination assessing retinal pigment epithelial hypopigmentation and foveal hypoplasia, and best corrected visual acuity (with cycloplegic refraction);</div></li><li class="half_rhythm"><div>Evaluation of the pigmentation status of the skin, especially the solar-exposed skin, and the adnexa (brows, lashes, and when appropriate extremity hair and pubic hair), linked to a (pediatric) dermatologic consultation for sun-protective clothing, lotions, and future self-care;</div></li><li class="half_rhythm"><div>Clinical genetics consultation to review natural history, pattern of inheritance and recurrence risks, and to clarify <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>.</div></li><li class="half_rhythm"><div>Parents should be assured repeatedly that the visual disability with OCA1 does not deteriorate over time, that changes in acuity are usually refractive in nature, that the nystagmus tends to dampen with age (but never disappears), that many children with OCA1B manifest slow improvement in acuity and some plateau by their teen years, and that intellectual disabilities are not a component of this group of disorders.</div></li></ul></div><div id="oca1.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Ophthalmologic care.</b> Correction with spectacles or (when age-appropriate) contact lenses of the refractive errors of either hyperopia or myopia and astigmatism found in most individuals with albinism can optimize visual acuity. Notably, visual acuity is never correctable to normal, but parents should be advised that the achievable acuity never deteriorates.</p><p>Strabismus surgery is usually not mandatory but may be performed if the strabismus is marked. Surgery may improve peripheral binocularity or appearance. When an anomalous null point creates a substantial face turn or head tilt, strabismus surgery may reposition the null point to a more central, straight-ahead location to allow more socially acceptable head position. Nystagmus surgery remains highly controversial; no comparative clinical trial has compared the surgical reduction of amplitude of nystagmus to the outcomes of the natural history of dampened nystagmus with age among those forms of albinism in which increasing pigment occurs normally over time.</p><p>Photodysphoria (discomfort in bright light; as distinct from "photophobia," which is painful aversion of light associated with intraocular inflammation) is common among all individuals with OCA; however, the severity of discomfort varies and is not completely concordant with the amount of pigment present in the iris or the skin.</p><ul><li class="half_rhythm"><div>Dark glasses or transition lenses may be helpful, but many individuals with albinism prefer to go without the tint because of the reduction in acuity from the dark lenses. Note: Going without dark glasses does not harm vision.</div></li><li class="half_rhythm"><div>Darkly tinted contact lenses do not improve visual function substantively because the reduction of transmission of the thin contact lens is no match for the density of a tinted spectacle lens.</div></li><li class="half_rhythm"><div>Most children with albinism should remain in mainstream classrooms, as long as the school attends to their special needs resulting from visual limitation. Preschoool evaluations allow teachers and parents to develop an Individual Education Plan (IEP). Neither Braille nor "white cane" mobility training is needed in the overwhelming majority of children with albinism.</div></li><li class="half_rhythm"><div>Additional classroom aids may include:</div><ul><li class="half_rhythm"><div>High contrast reading materials (black on white);</div></li><li class="half_rhythm"><div>Large font texts or xerographically enlarged worksheets;</div></li><li class="half_rhythm"><div>Preferential seating near the front of the class and work boards;</div></li><li class="half_rhythm"><div>Selective optical devices, especially mobile ones such as stand magnifiers and monocular telescopes, and closed circuit chip-camera televisions; and</div></li><li class="half_rhythm"><div>Computers and tablets with zoom-magnification text software.</div></li></ul></li></ul><p>A hat with a brim (such as a baseball hat with a visor) is helpful to reduce overhead glare, to reduce some photodysphoria, and to provide some sun protection to the face.</p></div><div id="oca1.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p><b>Skin care</b> in individuals with OCA1 is guided by the amount of pigment in the skin and the cutaneous response to sunlight.</p><p>For individuals with OCA1A, the white skin is completely devoid of melanin and needs to be protected whenever exposed to the sun. Sun exposure as short as five to ten minutes can be substantial in very sensitive individuals, and exposure of 30 minutes or more is usually substantial in less sensitive individuals. Prolonged periods in the sun require skin protection with clothing (hats with brims, long sleeves, pants, and socks) and sunscreens with a high SPF value (blocks with SPF 45-50+). Even early in life, a (pediatric) dermatologic consultation is warranted to teach parents about the use of sun-protective clothing and interpretation of the often confusing validity of numerical values and contents of sun-protective lotions and formulas.</p><p>For individuals with OCA1B, the amount of skin pigmentation varies and the use of sunscreen should correlate with skin pigmentation and the ability to tan. Skin that burns with sun exposure needs protection. An early (pediatric) dermatologic consultation is warranted.</p></div><div id="oca1.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>During the first few years of life, annual ophthalmologic examination, including assessment of refractive error and strabismus</div></li><li class="half_rhythm"><div>In adults, dermatologic surveillance of unusual skin thickening, hyperkeratosis, and erosive lesions that may be harbingers of skin cancer</div></li></ul></div><div id="oca1.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Other than the avoidance of prolonged solar exposure because of the enhanced damage to the skin and increasing cumulative risk of cutaneous neoplasms, no special precautions are needed.</p></div><div id="oca1.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#oca1.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="oca1.Pregnancy_Management"><h3>Pregnancy Management</h3><p>In classic OCA1 of either type, an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> mother who is pregnant needs no exceptional consideration. Similarly, a pregnancy affected with OCA1 requires no exceptional prenatal care.</p></div><div id="oca1.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="oca1.Genetic_Counseling"><h2 id="_oca1_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="oca1.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>OCA1 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="oca1.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes; therefore, each carries a single copy of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TYR</i>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, the sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual have a 25% chance of being affected, a 50% chance of being asymptomatic carriers, and a 25% chance of being unaffected and not carriers.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected clinically, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Offspring of an individual with OCA1 are obligate heterozygotes (carriers) for one of the parental pathogenic variants in <i>TYR</i>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each unaffected sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of that parent&#x02019;s disease-associated variant.</p></div><div id="oca1.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk family members is possible if both pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in the family have been identified.</p><p>Molecular genetic testing is not offered routinely to the reproductive partners of family members identified as carriers because of the difficulty of interpreting test results in an unaffected individual with a negative family history.</p></div><div id="oca1.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>Rarely, families displaying two-generation "pseudodominant" inheritance have been identified; this results from an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual having children with a reproductive partner who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (i.e., a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>).</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="oca1.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TYR</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="oca1.Resources"><h2 id="_oca1_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Organization of Albinism and Hypopigmentation (NOAH)</b></div><div>PO Box 959</div><div>East Hampstead NH 03826-0959</div><div><b>Phone:</b> 800-473-2310 (toll-free); 603-887-2310</div><div><b>Fax:</b> 800-648-2310 (toll-free)</div><div><b>Email:</b> info@albinism.org</div><div><a href="http://www.albinism.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.albinism.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/oculocutaneous-albinism" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Oculocutaneous albinism</a></div></li><li class="half_rhythm"><div><b>PanAmerican Society for Pigment Cell Research (PASPCR)</b></div><div><a href="http://www.paspcr.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.paspcr.org</a></div></li><li class="half_rhythm"><div><b>Xeroderma Pigmentosum Society, Inc (XP Society)</b></div><div><i>XP Society has material on their site related to UV protection/avoidance.</i></div><div>437 Syndertown Road</div><div>Craryville NY 12521</div><div><b>Phone:</b> 877-XPS-CURE (877-977-2873); 518-851-2612</div><div><b>Email:</b> xps@xps.org</div><div><a href="http://www.xps.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.xps.org</a></div></li><li class="half_rhythm"><div><b>eyeGENE - National Ophthalmic Disease Genotyping Network Registry</b></div><div><b>Phone:</b> 301-435-3032</div><div><b>Email:</b> eyeGENEinfo@nei.nih.gov</div><div><a href="https://eyegene.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nei.nih.gov/eyegene</a></div></li></ul></div><div id="oca1.Molecular_Genetics"><h2 id="_oca1_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="oca1.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Oculocutaneous Albinism Type 1: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1166/table/oca1.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca1.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_oca1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_oca1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_oca1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_oca1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_oca1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_oca1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_oca1.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7299" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TYR</i></a></td><td headers="hd_b_oca1.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7299" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">11q14<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_oca1.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P14679" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Tyrosinase</a></td><td headers="hd_b_oca1.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.retina-international.org/files/sci-news/tyrmut.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retina International Mutations of the Tyrosinase Gene</a><br /><a href="http://www.ifpcs.org/albinism/oca1mut.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Albinism Database Mutations of the tyrosinase gene</a></td><td headers="hd_b_oca1.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TYR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TYR</a></td><td headers="hd_b_oca1.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TYR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TYR</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="oca1.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="oca1.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Oculocutaneous Albinism Type 1 (<a href="/omim/203100,606933,606952" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1166/table/oca1.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__oca1.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/203100" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">203100</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALBINISM, OCULOCUTANEOUS, TYPE IA; OCA1A</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606933" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606933</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TYROSINASE; TYR</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606952" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606952</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALBINISM, OCULOCUTANEOUS, TYPE IB; OCA1B</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The reference transcript <a href="/nuccore/NM_000372.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000372.4</a> has five exons. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1166/#oca1.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Benign variants of <i>TYR</i> are known.</p><ul><li class="half_rhythm"><div>The benign variants c.575C&#x0003e;A (p.Ser192Tyr) and c.1205G&#x0003e;A (p.Arg402Gln) result in amino acid substitutions.</div></li><li class="half_rhythm"><div>The c.575C&#x0003e;A (p.Ser192Tyr) variant has not been associated with any pigmentation <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>The c.1205G&#x0003e;A (p.Arg402Gln) variant has been associated with an OCA1B <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in persons who are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on the other <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>; however, this association has not been shown to occur in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state in unaffected individuals.</div></li></ul><p><b>Pathogenic variants.</b> Hundreds of <i>TYR</i> pathogenic alleles have been reported [<a class="bk_pop" href="#oca1.REF.simeonov.2013.827">Simeonov et al 2013</a>]. Several have been found to be common to multiple families, while the majority have been identified in only a few families.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Tyrosinase is the key enzyme, catalyzing several steps in melanin synthesis, including the essential first and second steps: the hydroxylation of tyrosine to L-DOPA and the oxidation of L-DOPA to DOPA quinone. This is a copper-containing enzyme with activity limited to the melanosome within the melanocyte.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most pathogenic variants of <i>TYR</i> are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that produce enzyme with no catalytic activity (<i>TYR</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> variants or predicted to be subject to <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>-mediated decay) associated with the OCA1A <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> or small amounts of residual catalytic activity (<i>TYR</i> <a class="def" href="/books/n/gene/glossary/def-item/hypomorphic/">hypomorphic</a> variants) associated with the OCA1B phenotype. The mechanism for partial activity is currently being explored [<a class="bk_pop" href="#oca1.REF.chiang.2009.1590">Chiang et al 2009</a>, <a class="bk_pop" href="#oca1.REF.simeonov.2013.827">Simeonov et al 2013</a>].</p></div><div id="oca1.References"><h2 id="_oca1_References_">References</h2><div id="oca1.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.chiang.2009.1590">Chiang PW, Spector E, Tsai AC. Oculocutaneous albinism spectrum. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:1590–1.</span> [<a href="/pubmed/19533789" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19533789</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.creel.1990.193">Creel DJ, Summers CG, King RA. Visual anomalies associated with albinism. <span><span class="ref-journal">Ophthalmic Paediatr Genet. </span>1990;<span class="ref-vol">11</span>:193–200.</span> [<a href="/pubmed/2280977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2280977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.gr_nskov.2013.415">Gr&#x000f8;nskov K, Dooley CM, &#x000d8;stergaard E, Kelsh RN, Hansen L, Levesque MP, Vilhelmsen K, M&#x000f8;llg&#x000e5;rd K, Stemple DL, Rosenberg T. Mutations in <em>C10orf11</em>, a melanocyte-differentiation gene, cause autosomal-recessive albinism. <span><span class="ref-journal">Am J Hum Genet. </span>2013;<span class="ref-vol">92</span>:415–21.</span> [<a href="/pmc/articles/PMC3591853/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3591853</span></a>] [<a href="/pubmed/23395477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23395477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.gr_nskov.2007.43">Gr&#x000f8;nskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2007;<span class="ref-vol">2</span>:43–7.</span> [<a href="/pmc/articles/PMC2211462/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2211462</span></a>] [<a href="/pubmed/17980020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17980020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.gr_nskov.2009.1058">Gr&#x000f8;nskov K, Ek J, Sand A, Scheller R, Bygum A, Brixen K, Brondum-Nielsen K, Rosenberg T. Birth prevalence and mutation spectrum in danish patients with autosomal recessive albinism. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2009;<span class="ref-vol">50</span>:1058–64.</span> [<a href="/pubmed/19060277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19060277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.hutton.2008.2442">Hutton SM, Spritz RA. Comprehensive analysis of oculocutaneous albinism among non-Hispanic Caucasians shows that OCA1 is the most prevalent OCA type. <span><span class="ref-journal">J Invest Dermatol. </span>2008;<span class="ref-vol">128</span>:2442–50.</span> [<a href="/pmc/articles/PMC3515683/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3515683</span></a>] [<a href="/pubmed/18463683" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18463683</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.inagaki.2004.466">Inagaki K, Suzuki T, Shimizu H, Ishii N, Umezawa Y, Tada J, Kikuchi N, Takata M, Takamori K, Kishibe M, Tanaka M, Miyamura Y, Ito S, Tomita Y. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:466–71.</span> [<a href="/pmc/articles/PMC1182260/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1182260</span></a>] [<a href="/pubmed/14961451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14961451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.jeffery.1997.95">Jeffery G, Brem G, Montoliu L. Correction of retinal abnormalities found in albinism by introduction of a functional tyrosinase gene in transgenic mice and rabbits. <span><span class="ref-journal">Brain Res Dev Brain Res. </span>1997;<span class="ref-vol">99</span>:95–102.</span> [<a href="/pubmed/9088570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9088570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.kobayashi.2007.4261">Kobayashi T, Hearing VJ. Direct interaction of tyrosinase with Tyrp1 to form heterodimeric complexes in vivo. <span><span class="ref-journal">J Cell Sci. </span>2007;<span class="ref-vol">120</span>:4261–8.</span> [<a href="/pubmed/18042623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18042623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.newton.2001.981">Newton JM, Cohen-Barak O, Hagiwara N, Gardner JM, Davisson MT, King RA, Brilliant MH. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:981–8.</span> [<a href="/pmc/articles/PMC1274374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1274374</span></a>] [<a href="/pubmed/11574907" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11574907</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.pott.2003.137">Pott JW, Jansonius NM, Kooijman AC. Chiasmal coefficient of flash and pattern visual evoked potentials for detection of chiasmal misrouting in albinism. <span><span class="ref-journal">Doc Ophthalmol. </span>2003;<span class="ref-vol">106</span>:137–43.</span> [<a href="/pubmed/12678278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12678278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.rooryck.2008.583">Rooryck C, Morice-Picard F, Elcioglu NH, Lacombe D, Taieb A, Arveiler B. Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. <span><span class="ref-journal">Pigment Cell Melanoma Res. </span>2008;<span class="ref-vol">21</span>:583–7.</span> [<a href="/pubmed/18821858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18821858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.schmitz.2003.16">Schmitz B, Schaefer T, Krick CM, Reith W, Backens M, Kasmann-Kellner B. Configuration of the optic chiasm in humans with albinism as revealed by magnetic resonance imaging. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2003;<span class="ref-vol">44</span>:16–21.</span> [<a href="/pubmed/12506050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12506050</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.simeonov.2013.827">Simeonov DR, Wang X, Wang C, Seergeev Y, Dolinska M, Bower M, Fischer R, Winer D, Dubrovsky G, Balog JZ, Huizing M. hart R, Zein WM, Gahl WA, Brooks BP, Adams DR. DNA Variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics. <span><span class="ref-journal">Hum Mutat. </span>2013;<span class="ref-vol">34</span>:827–35.</span> [<a href="/pmc/articles/PMC3959784/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3959784</span></a>] [<a href="/pubmed/23504663" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23504663</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="oca1.REF.wei.2010.716">Wei A, Wang Y, Long Y, Guo X, Zhou Z, Zhu W, Liu J, Bian X, Lian S, Li W. A comprehensive analysis reveals mutational spectra and common alleles in Chinese patients with oculocutaneous albinism. <span><span class="ref-journal">J Invest Dermatol. </span>2010;<span class="ref-vol">130</span>:716–24.</span> [<a href="/pubmed/19865097" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19865097</span></a>]</div></li></ul></div></div><div id="oca1.Chapter_Notes"><h2 id="_oca1_Chapter_Notes_">Chapter Notes</h2><div id="oca1.Author_History"><h3>Author History</h3><p>Richard King, MD, PhD, FACMG; University of Minnesota (1999-2013)<br />Richard Alan Lewis, MD, MS (2013-present)</p></div><div id="oca1.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>16 May 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 October 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 December 2002 (rk) Revisions</div></li><li class="half_rhythm"><div>16 September 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 January 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>23 July 1999 (rk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1166</span><span class="label">PMID: <a href="/pubmed/20301345" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301345</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/x-oa/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/oca2/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1166&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1166/?report=reader">PubReader</a></li><li><a href="/books/NBK1166/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1166" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1166" style="display:none" title="Cite this Page"><div class="bk_tt">Lewis RA. Oculocutaneous Albinism Type 1. 2000 Jan 19 [Updated 2013 May 16]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1166/pdf/Bookshelf_NBK1166.pdf">PDF version of this page</a> (431K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#oca1.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#oca1.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#oca1.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#oca1.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#oca1.Genetically_Related_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related Disorders</a></li><li><a href="#oca1.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#oca1.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#oca1.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#oca1.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#oca1.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#oca1.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#oca1.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7299[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TYR</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1166+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1468358" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1468358" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1468358" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1468358" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301410" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 2</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 2<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lewis RA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301683" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 4</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous Albinism Type 4<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hayashi M, Suzuki T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17980020" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous albinism.</a><span class="source">[Orphanet J Rare Dis. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Oculocutaneous albinism.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Grønskov K, Ek J, Brondum-Nielsen K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2007 Nov 2; 2:43. Epub 2007 Nov 2.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301464" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hermansky-Pudlak Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hermansky-Pudlak Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Huizing M, Malicdan MCV, Gochuico BR, Gahl WA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301517" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ocular Albinism, X-Linked</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ocular Albinism, X-Linked<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lewis RA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301345" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301345" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0419cfdde089116955fa10">Oculocutaneous Albinism Type 1 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Oculocutaneous Albinism Type 1 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:24:15-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8D661DE0403F8100000000095B034C&amp;ncbi_session=CE8D661DE0419CF1_2395SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1166%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1166&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1166/&amp;ncbi_pagename=Oculocutaneous Albinism Type 1 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D661DE0419CF1_2395SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>